<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021614</url>
  </required_header>
  <id_info>
    <org_study_id>M-clip-2020-09</org_study_id>
    <nct_id>NCT05021614</nct_id>
  </id_info>
  <brief_title>Valveclip® Transcatheter Mitral Valve Repair Study</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of the Transcatheter Mitral Valve Repair System in Patients With Moderate and Above Degenerative Mitral Regurgitation at High Surgical Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai NewMed Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai NewMed Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the effectiveness and safety of the&#xD;
      transcatheter mitral valve repair system in the treatment of patients with moderate or above&#xD;
      degenerative mitral regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective,multi-center, single-arm, safety and performance clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of product</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy of product is defined as the proportion of participants meeting effective standards after surgery (freedom from death, mitral valve reoperation or MR&gt;2+ at 12 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of product</measure>
    <time_frame>30 days, 180 days, 2 to 5 years</time_frame>
    <description>Efficacy of product is defined as the proportion of participants meeting effective standards after surgery (freedom from death, mitral valve reoperation or MR&gt;2+ at 30 days, 180 days, 2 to 5 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiovascular related mortality</measure>
    <time_frame>30 days, 180 days, 1 year, 2 to 5 years</time_frame>
    <description>Cardiovascular related mortality after Transcatheter Mitral Valve Repairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe adverse events</measure>
    <time_frame>30 days, 180 days, 1 year, 2 to 5 years</time_frame>
    <description>Severe adverse events after Transcatheter Mitral Valve Repairment (including death, stroke, myocardial infarction, reoperation, instrumental non-selective cardiovascular surgery, renal failure, and adverse events related to transfemoral vein septal approach surgery, etc.）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Improvement</measure>
    <time_frame>30 days, 180 days, 1 year, 2 to 5 years</time_frame>
    <description>The 12-Item Short-Form Health Survey(SF-12)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Technical success</measure>
    <time_frame>immediate post-surgical</time_frame>
    <description>Technical success after Transcatheter Mitral Valve Repairment</description>
  </other_outcome>
  <other_outcome>
    <measure>Device success</measure>
    <time_frame>30 days、180 days、1 year</time_frame>
    <description>Device success after Transcatheter Mitral Valve Repairment</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success</measure>
    <time_frame>30 days</time_frame>
    <description>Procedural success after Transcatheter Mitral Valve Repairment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Mitral Valve Repair with Valveclip®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Valveclip® Transcatheter mitral valve repair</intervention_name>
    <description>Transcatheter mitral valve repair system</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe mitral regurgitation≥3+ (moderate or above degenerative mitral regurgitation&#xD;
             disease, or with stenosis is included);&#xD;
&#xD;
          2. Age≥70 years; or patients who are 60~70 years old, and the STS risk score indicate&#xD;
             that participants are at high risk of traditional surgery or cannot tolerate&#xD;
             traditional thoracotomy;&#xD;
&#xD;
        4) Left ventricular ejection fraction≥30%； 5) As assessed by multidisciplinary cardiac team&#xD;
        (at least two cardiac surgeons/one cardiologist), patients who are at extremely high-risk&#xD;
        or unsuitable for routine mitral valve surgery with evaluation; 6) Patients who understand&#xD;
        the purpose of the trial and volunteer to participate in, sign the informed consent form&#xD;
        and are willing to accept relevant examinations and clinical follow-ups.&#xD;
&#xD;
        Anatomy selection Criteria：&#xD;
&#xD;
          1. The regurgitant jet of mitral valve originates from the A2 and P2 (the lesions of&#xD;
             A2/P2 in mitral valve causes regurgitation);&#xD;
&#xD;
          2. The width of the mitral valve prolapsed area is ≤15mm, Height of Prolapse ≤10mm or&#xD;
             coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and&#xD;
             posterior leaflets&gt;1cm (conforming to EVEREST II recommended mitral valve&#xD;
             interventional edge-to-edge repair standards);&#xD;
&#xD;
          3. Effective mitral valve orifice area≥ 4.0cm2;&#xD;
&#xD;
          4. No obvious calcification of the mitral valve annulus and valve leaflets;&#xD;
&#xD;
          5. Patient's anatomical conditions allow transseptal approach.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous cardiac mitral valve surgery;&#xD;
&#xD;
          2. Patients with Infective endocarditis or having an active infection;&#xD;
&#xD;
          3. Patients with mitral regurgitation caused by pure mitral stenosis;&#xD;
&#xD;
          4. Combined with untreated severe coronary artery disease&#xD;
&#xD;
          5. Pulmonary hypertension (pulmonary artery systolic pressure&gt;70mmHg);&#xD;
&#xD;
          6. Patients with severe right heart failure;&#xD;
&#xD;
          7. Patients are extremely weak and cannot tolerate general anesthesia or are in shock&#xD;
             that circulatory support is needed;&#xD;
&#xD;
          8. Patients with hypertrophic cardiomyopathy, restrictive cardiomyopathy, and&#xD;
             constrictive pericarditis;&#xD;
&#xD;
          9. Patients receiving chronic dialysis;&#xD;
&#xD;
         10. Patients with clear coagulation dysfunction and severe coagulopathy;&#xD;
&#xD;
         11. Patients with clear contraindications to anticoagulant drugs;&#xD;
&#xD;
         12. Patients with stroke or transient ischemic attack within 30 days;&#xD;
&#xD;
         13. Echocardiography found any intracardiac mass, left ventricle or atrial thrombus;&#xD;
&#xD;
         14. Patients who require surgery or interventional therapy for other valvular lesions;&#xD;
&#xD;
         15. Patients with severe macrovascular lesions requiring surgical treatment;&#xD;
&#xD;
         16. Patients' imaging examinations suggest that the anatomy of the heart and valves are&#xD;
             inappropriate;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mao Chen, Chief</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chunyang Wang, CRA</last_name>
    <phone>(86)-21-20788668</phone>
    <email>cywang@newmed.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xuyang Xie</last_name>
    <phone>(86)-21-20788668</phone>
    <email>xyxie@newmed.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, West China Hospital, Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>mao Chen, Chief</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

